Ipsen SA, of Paris, said French regulatory authorities granted marketing approval of the six-month, sustained-release formulation of Decapeptyl (triptorelin embonate 22.5 mg) in locally advanced and metastatic breast cancer

OncoVista Innovative Therapies Inc., of San Antonio, Texas, said research conducted using its AdnaTest EMT1/StemCell product on blood samples of metastatic breast cancer patients receiving palliative chemotherapy, antibody or hormonal therapy showed that a major proportion of the circulating cancerous tumor cells in those patients had the expected biomarkers and tumor stem cell characteristics...Bavituximab is in Phase II trials for the treatment of advanced breast cancer and advanced lung cancer

The inhibition of the beneficial effect of ERb in breast cancer cells potentially could lead to unwanted outcomes for breast cancer patients who are treated with tamoxifen, the firm said

Cellceutix Corp., of Beverly, Mass., has successfully completed animal model tests on a taxane-resistant, estrogen receptor-negative breast cancer human cell line, MDA-MB-435s, using its pharmaceutical compound Kevetrin

Celprogen Inc., of San Pedro, Calif., isolated and propagated human triple negative breast cancer stem cells...Breast cancer is the most common malignancy among women in developed countries, affecting more than a million women per year worldwide

Avastin previously gained approval in colorectal, lung and breast cancers

CytRx Corp., of Los Angeles, said its investigational cancer drug INNO-206 caused a dramatic destruction of implanted tumors in an experimental animal model of breast cancer, performing considerably better than the broadly used and generally effective chemotherapeutic drug doxorubicin

CytRx Corp., of Los Angeles, said its investigational cancer drug INNO-206 caused a dramatic destruction of implanted tumors in an experimental animal model of breast cancer, performing considerably better than chemotherapeutic drug doxorubicin...to complete Quantum's Phase I/II trials on metastatic breast cancer now under way

Pixantrone is a major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines - the cornerstone therapeutics for lymphoma, leukemia and breast cancer - and other related chemotherapy agents

Amgen Inc., of Thousand Oaks, Calif., said the FDA has scheduled a Reproductive Health Drugs Advisory Committee meeting for Aug. 13 to review data supporting the biologics license application for denosumab, a RANK ligand inhibitor, in the prevention and treatment of postmenopausal osteoporosis and prevention and treatment of bone loss in patients undergoing hormone ablation for either prostate or breast cancer

Algeta ASA, of Oslo, Norway, reported research demonstrating that the alpha particle emitter thorium-227 linked to the monoclonal antibody trastuzumab (Herceptin, Genentech Inc.) selectively targeted and killed breast cancer cells...Data showed that 227TH-trastuzumab selectively targeted and bound HER2-presenting tumor cells in vitro and in mice with HER2-positive tumors, and the drug exerted a measurable and dose-dependent effect by killing HER2-positive breast cancer cells to which it was bound

These indications include certain breast cancers, basal cell carcinoma, squamous cell carcinoma, certain head and neck cancers and melanoma

Algeta ASA, of Oslo, Norway, reported research demonstrating that the alpha particle emitter thorium-227 linked to the monoclonal antibody trastuzumab (Herceptin, Genentech) selectively targeted and killed breast cancer cells...Data showed that 227TH-trastuzumab selectively targeted and bound HER2-presenting tumor cells in vitro and in mice with HER2-positive tumors, and the drug exerted a measurable and dose-dependent effect by killing HER2-positive breast cancer cells to which it was bound

Apthera Inc., of Scottsdale, Ariz., licensed NeuVax South Korean commercial rights in breast cancer to Kwang Dong Pharmaceutical Co...Apthera is planning a Phase III breast cancer trial with peptide-based immunotherapy product NeuVax

Clinical Data Inc., of Newton, Mass., said it established a research collaboration with the Dana-Farber Cancer Institute to validate the use of genetic variants in Fc gamma receptors, including FCGR3A, in predicting response to Herceptin (trastuzumab, Genentech Inc.) therapy in breast cancer patients

In an article published this month in the Journal of Breast Cancer Research and Treatment, "MUC1 is a Determinant of Trastuzumab (Herceptin) Resistance in Breast Cancer Cells," Minerva researchers reported that tumor cells that had grown resistant to anticancer drugs do so by overexpressing a growth factor receptor that they named MUC1

Under terms of the collaboration, Duke researchers will conduct genotyping research projects using the system to validate single-nucleotide polymorphisms (SNPs) that are related to breast cancer

Tigris Pharmaceuticals Inc., of Bonita Springs, Fla., said data involving its candidate AFP464, an aminoflavone prodrug, showed that when the drug is administered after Zolinza (vorinostat, Merck & Co. Inc.), estrogen receptors were reinstated in receptor-negative breast cancer cells so that treatment also was effective in fighting ER-negative disease

Domainex Ltd., of Cambridge, UK, announced a discovery collaboration with the research charity Breakthrough Breast Cancer Research Centre and The Institute of Cancer Research in London to identify and develop inhibitors of two recently validated breast cancer targets, tankyrase and IKK-epsilon